Eflornithine

Generic Name: Eflornithine

Brand Names: Vaniqa

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂F_₂N_₂O_₂

CAS Number: 70052-12-9

Unique Ingredient Identifier: ZQN1G5V6SR

Background: Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines.

Indication: Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).

Associated Conditions: Meningoencephalitic stage Trypanosoma brucei gambiense infection

Associated Therapies: Hair removal therapy

Clinical Trials

Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female

Phase 4

Recruiting

Conditions: Hirsuitism

Interventions: Combination Product: Intense pulse light and eflornithine
Drug: Eflornithine Topical

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Khyber Teaching Hospital

Target Recruit Count: 122

Registration Number: NCT06976424

Locations: 🇵🇰
Khyber Teaching Hospital, Peshawar, KPK, Pakistan
🇵🇰
Khyber Teachinng Hospital, Peshawar, KPK, Pakistan

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma Recurrent
Ewing's Tumor Recurrent

Interventions: Drug: DFMO

First Posted Date: 2025-03-25

Last Posted Date: 2025-05-11

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 15

Registration Number: NCT06892678

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: DFMO
Drug: testosterone cypionate
Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
Drug: Enzalutamide

First Posted Date: 2023-09-28

Last Posted Date: 2025-02-25

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 50

Registration Number: NCT06059118

Locations: 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1

Recruiting

Conditions: Glioblastoma, IDH-wildtype
Glioblastoma Multiforme
Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
GBM

Interventions: Drug: Eflornithine (Dose Level 2)
Drug: Eflornithine (Dose Level 1)
Drug: Eflornithine (Dose Level -1)
Drug: Temozolomide

First Posted Date: 2023-05-30

Last Posted Date: 2024-04-18

Lead Sponsor: Orbus Therapeutics, Inc.

Target Recruit Count: 66

Registration Number: NCT05879367

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

and more 5 locations

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Early Phase 1

Recruiting

Conditions: Diffuse Glioma
Malignant Glioma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Eflornithine
Procedure: Magnetic Resonance Imaging
Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate
Procedure: Resection
Device: Microdialysis
Procedure: Placement

First Posted Date: 2023-02-08

Last Posted Date: 2025-04-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 15

Registration Number: NCT05717153

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

Phase 2

Recruiting

Conditions: Type 1 Diabetes

Interventions: Drug: Placebo
Drug: DFMO

First Posted Date: 2022-10-26

Last Posted Date: 2025-04-02

Lead Sponsor: Emily K. Sims

Target Recruit Count: 70

Registration Number: NCT05594563

Locations: 🇺🇸
Barbara Davis Center, Aurora, Colorado, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
IU Health Riley Hospital for Children, Indianapolis, Indiana, United States

and more 3 locations

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Phase 1

Terminated

Conditions: Advanced Cancer
DIPG Brain Tumor
Ovary Cancer
Mesotheliomas Pleural
Papillary Thyroid Cancer
Gastric Cancer
Mesothelioma Peritoneum
Cancer
Nsclc
Cervical Cancer

Interventions: Drug: AMXT1501
Drug: DFMO

First Posted Date: 2022-08-15

Last Posted Date: 2024-12-24

Lead Sponsor: Aminex Therapeutics, Inc.

Target Recruit Count: 15

Registration Number: NCT05500508

Locations: 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Mayo Clinic - Florida, Jacksonville, Florida, United States

and more 4 locations

Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial

Phase 4

Terminated

Conditions: Pseudofolliculitis Barbae

Interventions: Drug: Eflornithine Topical
Drug: Placebo Eflornithine Topical

First Posted Date: 2020-05-27

Last Posted Date: 2024-01-31

Lead Sponsor: Walter Reed National Military Medical Center

Target Recruit Count: 9

Registration Number: NCT04403282

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Phase 2

Recruiting

Conditions: Neuroblastoma

Interventions: Drug: Eflornithine

First Posted Date: 2020-03-10

Last Posted Date: 2024-08-06

Lead Sponsor: Giselle Sholler

Target Recruit Count: 131

Registration Number: NCT04301843

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
UCSF Benioff Children's Hospital Oakland-, Oakland, California, United States
🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States

and more 25 locations

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Phase 2

Active, not recruiting

Conditions: High Risk Neuroblastoma
Refractory Neuroblastoma
Recurrent Neuroblastoma

Interventions: Biological: Dinutuximab
Drug: Irinotecan Hydrochloride
Drug: Eflornithine Hydrochloride
Biological: Sargramostim
Drug: Temozolomide

First Posted Date: 2019-01-07

Last Posted Date: 2025-04-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 94

Registration Number: NCT03794349

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 143 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy